Regeneron Pharmaceuticals Inc is a leading biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. The company's mission is to leverage its proprietary technologies and scientific expertise to create transformative therapies that improve patient outcomes. Regeneron's strategy emphasizes a robust pipeline of biologic drugs, particularly in the fields of ophthalmology, immunology, and oncology. Through strategic collaborations and a commitment to research and development, Regeneron aims to address unmet medical needs and enhance the quality of life for patients worldwide.

REGENERON PHARMACEUTICALS INC

Regeneron Pharmaceuticals is making headlines with the recent approval from the European Commission for its lymphoma treatment, odronextamab, branded as Ordspono. This dual-acting bispecific antibody is now authorized to treat adults with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma across 27 EU nations. The approval follows promising...

Regeneron Gains European Approval for Lymphoma Drug Ordspono, Boosting Stock Performance Amid Challenges in U.S. Market